Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Boehringer Ingelheim Stories

2013-09-05 16:25:53

Mobile Dog Heart Health Unit Veterinary Cardiologist to Provide Free Heart Screenings at BART Duathalon ST. JOSEPH, Mo., Sept. 5, 2013 /PRNewswire/ -- On Saturday, September 14, a veterinary cardiologist is going to the dogs in New Brighton. The Mobile Dog Heart Health Tour will stop at the 2013 BART Duathlon to perform free dog heart examinations at Long Lake Regional Park. In addition to providing free heart health screenings, the veterinary cardiologist - one of only a handful of...

2013-09-03 08:27:59

PRADAXA continues to drive Boehringer Ingelheim's commitment to innovation and research in cardiovascular diseases RIDGEFIELD, Conn., Sept. 3, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today confirmed research currently underway for Pradaxa® (dabigatran etexilate mesylate) in new cardiovascular patient populations, as well as robust plans to gather real-world evidence in patients with non-valvular atrial fibrillation (NVAF). These plans are the cornerstone of an...

2013-09-01 04:20:15

RIDGEFIELD, Conn., Sept. 1, 2013 /PRNewswire/ -- Today, data from the RE-ALIGN(TM) trial of dabigatran etexilate mesylate in patients with mechanical prosthetic heart valves were presented at the European Society of Cardiology (ESC) congress in Amsterdam, Netherlands, and published online in the New England Journal of Medicine. As part of Boehringer Ingelheim Pharmaceuticals, Inc.'s ongoing commitment to transparency, we previously announced on December 11, 2012, that this trial had been...

2013-08-28 08:26:27

RIDGEFIELD, Conn., Aug. 28, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for Pradaxa® (dabigatran etexilate mesylate) for its use in patients with deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT and PE are collectively referred to as venous thromboembolism (VTE), which is the third most common cardiovascular disorder after...

2013-08-23 12:23:55

RIDGEFIELD, Conn., Aug. 23, 2013 /PRNewswire/ -- Boehringer Ingelheim will present five abstracts at the ESC Congress 2013, organized by the European Society of Cardiology, taking place from August 31 to September 4, in Amsterdam, Netherlands, providing additional data about Pradaxa® (dabigatran etexilate mesylate) capsules. "The broad range of data being presented at this year's ESC further provides important new insights about PRADAXA," said Sabine Luik, MD, senior vice president,...

2013-08-22 12:27:40

RIDGEFIELD, Conn., Aug. 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. has announced that Gilotrif(TM) (afatinib) tablets for oral use will be commercially available in the U.S. the week of September 2. The U.S. Food and Drug Administration (FDA) approved GILOTRIF on July 12, 2013 as a new first-line -- or initial -- treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an...

2013-08-19 08:27:49

JERUSALEM, Aug. 19, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today the appointment of B. J. Bormann, Ph.D., to its Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20130730/630769) Dr. Bormann has had a distinguished and extensive career in the pharmaceutical industry. Most recently, she served as Senior Vice President and Worldwide Head of Therapeutic Alliances and Strategic Partnerships at Boehringer...

2013-08-15 12:28:10

Phase III safety and efficacy data of TRADJENTA® (linagliptin) tablets in elderly people with type 2 diabetes published in The Lancet RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 15, 2013 /PRNewswire/ -- Data published in The Lancet showed that elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (TRADJENTA(®)), marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY), experienced...

2013-08-15 08:29:31

Study program to assess safety and effectiveness of oral anticoagulants, including Pradaxa® (dabigatran etexilate mesylate), in U.S. patients with non-valvular atrial fibrillation RIDGEFIELD, Conn., Aug. 15, 2013 /PRNewswire/ -- Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care,...

2013-08-13 08:28:51

Boehringer Ingelheim puts a cutting-edge perspective on vaccines with a revolutionary low-dose vaccine line that improves the overall vaccine experience for dogs. ST. JOSEPH, Mo., Aug. 13, 2013 A new, revolutionary vaccine line is now available that contains the same vaccine protection you've come to expect against deadly pet diseases with 50 percent less volume per dose by using innovative improvements to the manufacturing process. (Photo:...